Differential Expression of CHL1 Gene during Development of Major Human Cancers by Senchenko, Vera N. et al.
Differential Expression of CHL1 Gene during
Development of Major Human Cancers
Vera N. Senchenko
1, George S. Krasnov
1, Alexey A. Dmitriev
1, Anna V. Kudryavtseva
1, Ekaterina A.
Anedchenko
1, Eleonora A. Braga
2, Irina V. Pronina
2, Tatiana T. Kondratieva
3, Sergey V. Ivanov
4,
Eugene R. Zabarovsky
1,5*, Michael I. Lerman
6
1Laboratory of Structural and Functional Genomics, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia, 2Laboratory of Molecular
Diagnosis, Russian State Genetics Center GosNIIgenetika, Moscow, Russia, 3Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia,
4Cardiothoracic Surgery Department, NYU Langone Medical Center, New York, New York, United States of America, 5Department of Microbiology, Tumor and Cell
Biology, Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institute, Stockholm, Sweden, 6Hematology Branch, National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
Background: CHL1 gene (also known as CALL) on 3p26.3 encodes a one-pass trans-membrane cell adhesion molecule
(CAM). Previously CAMs of this type, including L1, were shown to be involved in cancer growth and metastasis.
Methodology/Principal Findings: We used Clontech Cancer Profiling Arrays (19 different types of cancers, 395 samples) to
analyze expression of the CHL1 gene. The results were further validated by RT-qPCR for breast, renal and lung cancer. Cancer
Profiling Arrays revealed differential expression of the gene: down-regulation/silencing in a majority of primary tumors and
up-regulation associated with invasive/metastatic growth. Frequent down-regulation (.40% of cases) was detected in 11
types of cancer (breast, kidney, rectum, colon, thyroid, stomach, skin, small intestine, bladder, vulva and pancreatic cancer)
and frequent up-regulation (.40% of cases) – in 5 types (lung, ovary, uterus, liver and trachea) of cancer. Using real-time
quantitative PCR (RT-qPCR) we found that CHL1 expression was decreased in 61% of breast, 60% of lung, 87% of clear cell
and 89% papillary renal cancer specimens (P,0.03 for all the cases). There was a higher frequency of CHL1 mRNA decrease
in lung squamous cell carcinoma compared to adenocarcinoma (81% vs. 38%, P=0.02) without association with tumor
progression.
Conclusions/Significance: Our results suggested that CHL1 is involved in the development of different human cancers.
Initially, during the primary tumor growth CHL1 could act as a putative tumor suppressor and is silenced to facilitate in situ
tumor growth for 11 cancer types. We also suggested that re-expression of the gene on the edge of tumor mass might
promote local invasive growth and enable further metastatic spread in ovary, colon and breast cancer. Our data also
supported the role of CHL1 as a potentially novel specific biomarker in the early pathogenesis of two major histological
types of renal cancer.
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Introduction
Cancer-associated genes fall into two main categories: cancer-
causing genes that drive malignant transformation and maintain
tumor growth, and cancer progression genes that orchestrate local
invasion and further spread of metastatic cells and growth of
distant metastases [1,2,3]. The CHL1 gene – close homolog of L1,
also known as CALL - cell adhesion L1-like (GenBank Accession
No. NM_006614.2) encodes a one-pass trans-membrane cell
adhesion molecule (CAM) capable of both homotypic and
heterotypic binding. The protein encoded by this gene is a
member of the L1 gene family of neural cell adhesion molecules. It
is a neural recognition molecule that may be involved in signal
transduction pathways. CHL1 is expressed in normal tissues
besides the brain and is expressed in a variety of human cancer cell
lines and primary tumor tissues [4,5]. It was also shown that the
gene is involved in general cognitive activities (g/IQ) [6,7] and
some neurological diseases (i.e. schizophrenia [8]). The deletion of
one copy of this gene may be responsible for mental defects in
patients with 3p- syndrome. Recently several CAMs including L1
were shown to be involved in cancer growth and metastasis [9,10].
CHL1 is located at 3p26, a region that is shown to harbor a
candidate for prostate cancer susceptibility in Finnish prostate
cancer families, although no mutations were detected in the coding
part of the gene [11]. Thus, these reports suggest that CHL1 plays
a role in cancer development [12], not only in neuronal activities.
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e15612Previously, in collaboration with Dr. Helen S. Smith, we
performed a deletion mapping of the short arm of chromosome
3 on a panel of breast cancers and delineated three regions as
harboring breast cancer candidate tumor suppressor genes (TSG),
namely, 3p24-26, 3p21-22, and 3p12-13 [13,14,15,16]. Then we
cloned the CHL1 (CALL) gene in 1997/1998 and analyzed its
expression in mouse development and performed extensive
bioinformatics analysis [5].
Here we provided a comprehensive study of CHL1 mRNA
expression using two methods. Qualitative analysis was performed
using Clontech Cancer Profiling Arrays, and further real time
quantitative PCR (RT-qPCR) was employed for validation of the
microarray data for three major cancer types: non-small cell lung
cancer (NSCLC), breast cancer (BC), and renal cell carcinomas
(RCC). Our results suggested a dual role of the CHL1 in
tumorigenesis: it may contribute to initial tumor growth and then
to progression and finally tumor spread/metastasis. The data
further supported the role of CHL1 as a potentially novel specific
biomarker in the early pathogenesis of two major histological types
of renal cancer.
The work is dedicated to the memory of Dr. Helen S. Smith.
Results
In silico analysis of CHL1 expression in normal and tumor
tissues
The vast public expression databases allow to detect and
quantify the expression of most if not all known RefSeq genes
(,20,000) in normal and tumor tissues. We used several public
web-based servers to analyze mouse and human CHL1 expression
[17,18,19,20]. The data shows that CHL1 is expressed in many
normal adult and fetal tissues besides the brain and peripheral
nervous system [17,19]. Variable expression was seen in many
tumors; it was especially high in a melanoma cell line G361.
According to Oncomine [18] preliminary data based on micro-
array analysis, the CHL1 expression also varies in several major
cancer types – renal [21,22], cervical [23], colon [24,25], ovary
[26], lung [27,28], stomach [29] and breast [30,31] cancer. The
Oncomine also showed co-expression of CHL1 with another
known cancer metastasis-associated gene, lysyl oxidase (LOX) [32]
in metastatic melanoma.
Investigation of CHL1 expression with Cancer Profiling
Arrays
We used Cancer Profiling Arrays I and II (Clontech) to test the
CHL1 expression in a large sample of human primary tumors
including breast, lung, kidney, ovary, colon, stomach and others
(Fig. 1). Only 395 samples of 486, including 90 metastatic tumors
and 12 metastases were informative. We first showed that the
change of CHL1 expression in all studied tumors compared to the
matched non-cancerous (normal) tissues was statistically significant
(P,0.05, Fisher exact test or x
2 criteria).
Down-regulation. As demonstrated by Cancer Profiling
Arrays data in Figures 1 and 2, a high percentage of patients
displayed a down-regulation of CHL1 expression in breast, kidney,
rectum, colon, thyroid, stomach, skin, small intestine, bladder,
vulva and pancreatic cancer. The results of the microarray data
analysis were presented for 11 types of cancer in Table 1. In total,
a statistically significant decrease of CHL1 expression was found in
breast cancer - 71% (45 of 63 cases), colon - 48% (23 of 48),
rectum - 50% (14 of 28), thyroid - 69% (11 of 16), kidney - 75%
(21 of 28) and small intestine – 67% (6 of 9) cancers. Importantly, a
statistically significant increase of down-regulation frequency was
shown in samples with metastases compared to samples without
metastases in colon (83% vs. 36%, P=0.01) and rectum (75% vs.
31%, P=0.05) cancers. The same tendency was found in ovary
cancer (60% vs. 19%, P=0.17).
Up-regulation. The CHL1 up-regulation (frequency from
20% to 100%) was found in lung, ovary, uterus, liver, skin,
prostate, stomach, cervix and trachea cancers. However, the
increase of the CHL1 mRNA level was statistically significant only
in lung cancer 264% (16 of 25, P,0.01). The majority of such
cases (14 of 22, P,0.01) were found in different histotypes of
NSCLC (ADC, BAC, SCC) at the Stage I. Also we observed
several cases of CHL1 up-regulation in metastatic tumors
(stomach, lung, trachea, ovary and uterus, Table 1). Thus, the
cases with CHL1 up-regulation could serve as examples of CHL1
involvement both in initial and possibly in further progression and
invasive tumor growth.
Deregulation. In uterus and ovary cancer the frequency of
up- and down-regulation was close (41% and 30%, 46% and 27%,
respectively). In ovary cancer the down-regulation was a prevalent
event (52%) in samples without metastases, on the contrary the up-
regulation was prevalent (60%) in the group of metastatic tumors.
In stomach cancer a statistically significant change of CHL1
expression (both up- and down-regulation) was shown in the group
with metastases relative to the group without metastases (88% vs.
45%, P=0.02).
Metastases. We observed re-expression of the CHL1 in 4 of
12 metastases (first coordinate) along with low CHL1 mRNA level
in primary tumor (second coordinate): in ovary (24K/24L), colon
(14O/14P, 14V/14W) and breast (4I/4J, Fig. 1, Array I). In
addition, we also found silencing of the gene expression in both
metastasis and primary tumors, for example, breast cancer (4G/
4H, 4K/4L).
The CHL1 expression in breast, lung and renal cancer
tissues studied using RT-qPCR
The CHL1 mRNA content was decreased in the majority of
studied tumor samples compared to normal samples but in some
tumor samples the CHL1 expression was up-regulated (Fig. 3. A, B
and C).
Breast cancer (BC). We found that the CHL1 mRNA level
was decreased in 61% (14 of 23, P,0.03), increased in 22% (5 of
23) and not changed in 17% (4 of 23) of samples. Maximal
decrease of the CHL1 mRNA level was 20-fold, maximal increase
was 34-fold. There was no evident correlation between the change
of the CHL1 expression and the tumor progression (Fig. 3 A).
Non-small cell lung cancer (NSCLC). The CHL1 mRNA
level was decreased in 60% (18 of 30, P,0.02) and was normal in
33% (10 of 30), i.e. less than 2-fold changes. The decrease or
increase of the mRNA level was detected neither in lung non-
cancerous (normal) matched tissues nor in tissues from cancer free
healthy donors. However, for two histological subtypes of NSCLC
(ADC and SCC) the frequency of the mRNA changes was
different. Down-regulation was observed in 38% (5 of 14) of ADC
samples. The increase of the CHL1 mRNA (7-fold) was detected
only in one ADC sample. On the contrary, in SCC samples the
CHL1 expression was significantly decreased in 81%, (13 of 16,
P,0.02). LD (level of mRNA decrease) varied from 2 to 100-fold
in ADC and from 2 to 44-fold in SCC. There was a more
significant increase of FD (frequency of mRNA decreases) values in
SCC as compared to ADC (81% vs. 38%, P=0.02) without
noticeable association with tumor progression (Fig. 3, B and
Table 2).
Clear cell renal cell carcinoma (CC-RCC), papillary renal
cell carcinoma (pRCC) and renal carcinoma cell lines. A
significant decrease (from 3 to 302-fold) of CHL1 mRNA was
Differential Expression of the CHL1 Gene
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e15612Differential Expression of the CHL1 Gene
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e15612detected in 87% (26 of 30, P,0.01) of CC-RCC specimens and
89% (8 of 9, P,0.02) of pRCC specimens with LDav (geometric
mean of LD) equal to 18 and 19-fold respectively (Fig. 3, C).
Therefore we could conclude that the frequency and the average
level of the CHL1 expression decrease were similar for two major
histological types of renal cancer, CC-RCC and pRCC. The LDav
value was significant in all RCC tumors at all developmental stages
independent of metastasis presence (Table 3). In CC-RCC with or
without metastases, the FD and LDav values were similar.
The estimates of the CHL1 mRNA levels in seven renal cancer
cell lines revealed strong down-regulation of this gene: 80-fold
(Caki2, KRC/Y), about 1000-fold (TK164) and total silencing
(TK10, KH39, HN4, Caki1, Fig. 4).
Comparison of microarrays and RT-qPCR data for breast,
renal and lung cancer
The microarray data for 61 BC, 23 RCC and 25 NSCLC
samples were compared with RT-qPCR data for 23 BC, 30 CC-
RCC and 30 NSCLC samples. In our array study a significant
CHL1 down-regulation was shown for most of RCC samples; up-
regulation was observed in 3 cases only. Our results also showed
the down-regulation of CHL1 in most of BC samples independent
of the presence of metastases and up-regulation in 7 tumors only.
Almost the same results were obtained using RT-qPCR. There
were similarities between array and quantitative data for renal and
breast cancer (Table 4).
Cancer Profiling Arrays I and II include a very heterogeneous
group of lung cancer with different histological subtypes: BAC,ADC,
SCC, carcinoid with Stage I and II, only two metastatic tumors and
limited number of specimens of each subtype. Overall, there were 15
SCC and 5 ADC which we could compare with RT-qPCR data. We
found an up-regulation in 11 SCC (6 of 11 were identified as Stage I)
and 4 ADC (3 ADC were Stage I as well); down-regulation in 2 SCC
(13%) and 1 ADC (25%, Fig. 1). Recently, we showed an up-
regulation of several TSG on 3p in lung ADC at Stage I. These
tumors were characterized with high differentiation grade [33]. On
the other hand, according to the RT-qPCR data frequency of
decreased expression was 38% (5 of 14 cases) in ADC and 81% (13 of
16 cases, P,0.02) in SCC (see Table 2). An up-regulation was
detected only in 7% (1 of 14 cases) ADC and never in SCC.
Discussion
CHL1, located at 3p26.1, belongs to the family of cell adhesion
molecules (CAM) – cell surface proteins mediating cell-cell and
Figure 2. Distribution of primary tumors with different CHL1 mRNA level alterations. Fraction of tumors with CHL1 up-regulation is
showed with red, down-regulation – green, mRNA level retention – yellow. Data revealed with Clontech Microarray analysis. Asterisks (*) show
statistically significant differences between frequencies of CHL1 expression changes with up- and down-regulation.
doi:10.1371/journal.pone.0015612.g002
Figure 1. Results of microarray analysis of CHL1 mRNA level in different types of cancer. Abbreviations used: ADC - adenocarcinoma,
ASC - adenosquamous carcinoma, BAC - bronchiolo-alveolar adenocarcinoma, C - carcinoma, CAC - cystadenocarcinoma, CC-ADC - clear cell
adenocarcinoma, EDST - endodermal sinus tumor, ENB - epithelial nephroblastoma, ESS - endometrial stromal sarcoma, FAC - follicular
adenocarcinoma, FS - fibrosarcoma, I-DC - infiltrating ductal carcinoma, I-IDC - infiltrating intraductal carcinoma, I-LC - infiltrating lobular carcinoma,
LC - lobular carcinoma , LDC - mixed lobular-ductal carcinoma, LM - leiomyoma, M - malignant melanoma, MAC - mucinous adenocarcinoma, MBC -
mucinous borderline carcinoma, MC - medullary carcinoma, MMMT - malignant mixed Mullerian tumor, NI-IDC - noninfiltrating intraductal carcinoma,
PAC - papillary adenocarcinoma, PC - papillary carcinoma, PSC - papillary serous carcinoma, PSCA - papillary serous cystadenoma, PSCAC - papillary
serous cystadenocarcinoma, RCC - renal cell carcinoma, S - seminoma, SC - serous carcinoma, SCAC - serous cystadenocarcinoma, SCC - squamous cell
carcinoma, TAC - tubular adenocarcinoma, TC - tubular carcinoma, TCC - transitional cell carcinoma, UBT - uterus benign tumor. Asterisks (*) show
samples with metastases. **G361 – a melanoma cell line. The boxed samples indicate a matched normal (left) - primary tumor (bottom right) pair with
an associated metastatic sample (upper right corner of a box). T - tumor samples; N - matched normal control specimens.
doi:10.1371/journal.pone.0015612.g001
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CHL1) and functions have been implicated in development of
different tumor types, for example, melanoma [34], ovary [9,35],
prostate [11] and colon cancer [36]. According to [9], the
evaluation of LOH patterns in serous epithelial ovarian cancer
(EOC) suggested that CHL1 is a tumor suppressor candidate
(TSG). The studies published by us and other authors (see
Introduction) suggested that the CHL1 gene could be one of the
putative tumor suppressor genes localized on human chromosome
3 [12]. However, overexpression of CHL1 was observed in serous
EOC samples [9]. Furthermore, L1 CAM overexpression in
malignant melanoma was shown to be associated with metastases
[34].
According to Oncomine preliminary microarray expression
data [17] along with the prevalent CHL1 down-regulation in
several tumors (RCC, lung SCC, colon ADC), the overexpression
of CHL1 was found in melanoma. The differential expression was
observed in lung ADC [26], cervical [22] and breast [29,30]
cancer.
Based on this data, we hypothesized that CHL1 and other
recognition receptors of this type might have dual roles in cancer:
in early pre-invasive growth they could serve as TSG and are
silenced; later at invasion and metastasis stages these genes might
be re-expressed on the edge of the tumor to drive local invasion
and enable metastatic spread.
This hypothesis was analyzed in the current study using a
combination of preliminary expression screening in 19 different
types of epithelial tumors with commercial microarrays (altogether
395 informative samples, Table 1) and evaluation of the CHL1
mRNA expression in primary tumors using RT-qPCR. This
method is widely used to corroborate disease-associated expression
signatures derived from microarrays. Furthermore, this technology
is well suited for translating microarrays data into accurate and
quantitative, clinically useful assays [37].
We showed here that the expression of CHL1 was deregulated in
major epithelial malignancies (76%, P,0.01, including 54%
down-regulation cases according to microarray data). Statistically
significant FD values were shown for breast, colon, rectum,
thyroid, kidney and small intestine cancer (Table 1). For three
social significant/important cancer types – breast, kidney and lung
microarray data were validated by RT-qPCR. There was a good
concordance between data of two methods for kidney and breast
cancer. According to Oncomine microarray data the significant
decrease of CHL1 expression level in CC-RCC samples was shown
as well.
Clontech Microarray (overexpression in 64% lung cancer
samples) and RT-qPCR (down-regulation in 38% of ADC and
in 81% of SCC samples) were not in concord because different
cancer subtypes were present in studied microarray samplings.
The disagreement between arrays and RT-qPCR data for
NSCLC could also result from non-homogeneous samples with
different content of normal cells as well as limited number of
specimens and may be statistically non-significant. Although these
data are not statistically valid they could reflect important trends
and associations.
However there was a rather good agreement between our
quantitative results for lung cancer and Oncomine data [17] for
two major lung cancer histotypes – ADC and SCC.
It is important to note that Oncomine exploits microarrays
based on completely different platform than Clontech Cancer
Profiling Arrays. Traditional microarrays (Affymetrix, Agi-
lent) contain a number of various gene probes immobilized on
glass slides. Only one cDNA sample can be hybridized with
the slide. On the contrary, Clontech Cancer Profiling Arrays
contain a number of immobilized cDNA samples from
various tumor and normal tissues. Oncomine includes
traditional microarrays data making possible genome-wide
analysis of a limited number of samples and Cancer Profiling
Arrays enable analysis of one gene in many tumors in one
experiment.
According to the Clontech Microarray data, the mRNA level
increase was observed for several tumor types – uterus, ovary,
colon, stomach, thyroid, lung, kidney, and trachea – mainly for
non-metastatic tumors. However, also there were frequent cases of
the CHL1 mRNA level increase in metastatic tumors, for example,
in stomach and lung cancer.
Table 1. Summary of CHL1 expression in 11 tumor types as measured with the Clontech Cancer Profiling Arrays I and II.
Cancer No metastases With metastases *P Totally **P
Down Up Down Up Down Up
Breast 64 (25/39) 13 (5/39) 83 (20/24) 4 (1/24) 0.25 71 (45/63) 10 (6/63) ,0.01, x
2
Uterus 29 (12/42) 41 (17/42) 50 (1/2) 50 (1/2) 0.62 30 (13/44) 41 (18/44) 0.37
Ovary 19 (4/21) 52 (11/21) 60 (3/5) 20 (1/5) 0.17 27 (7/26) 46 (12/26) 0.25
Colon 36 (13/36) 11 (4/36) 83 (10/12) 8 (1/12) 0.01 48 (23/48) 10 (5/48) ,0.01
Rectum 31 (5/16) 6 (1/16) 75 (9/12) 8 (1/12) 0.05 50 (14/28) 7 (2/28) ,0.01
Stomach 28 (5/18) 17 (3/18) 59 (10/17) 29 (5/17) 0.02 43 (15/35) 23 (8/35) 0.13
Thyroid 58 (7/12) 19 (3/12) 100 (4/4) 0 (0/4) 0.30 69 (11/16) 19 (3/16) 0.01
Lung 18 (4/22) 64 (14/22) 33 (1/3) 67 (2/3) 0.65 20 (5/25) 64 (16/25) ,0.01
Kidney 70 (16/23) 18 (5/23) 100 (5/5) 0 (0/5) 0.36 75 (21/28) 18 (5/28) ,0.01
Trachea 0 (0/1) 100 (1/1) 0 (0/2) 100 (2/2) 6 0 (0/3) 100 (3/3) 6
Small intestine 60 (3/5) 20 (1/5) 75 (3/4) 0 (0/4) 0.64 67 (6/9) 11 (1/9) 0.05
Note: *P – p-parameter, characterized the difference between group with metastases and group without metastases, taking into account 3 possible events: decrease,
increase and retention of mRNA level in tumor samples comparing to adjusted normal samples. P-parameter calculated using x
2 method.
**P – p-parameter, characterized the difference between group of tumor samples and group of adjusted normal samples, taking into account prevalent process
(decrease or increase of mRNA level). P-parameter calculated using Fisher exact test for all cancers, except breast cancer.
Bold – the most significant changes.
doi:10.1371/journal.pone.0015612.t001
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available for analysis cases (i.e. when a primary tumor and
metastasis for the same patient were accessible) we detected an
increased CHL1 expression in metastasis compared to primary
tumor (ovary, colon and breast). Similar results were recently
reported for the metastasis-associated gene lysyl oxidase (LOX),
whose expression was associated both with tumor suppression and
tumor progression depending on transformation status [32]. The
overexpression of another cell adhesion molecule L1 gene was
associated with metastasis in malignant melanoma [34].
Cancer is a fatal disease whereby invasive local tumor growth
and metastatic spread to distant vital organs resulting in dormant
and/or active growth and inevitable death of patients. Contrary to
previous models new evidence suggested that metastatic cells
might be created already during initial growth of a primary local
tumor. These cells then succeed in cell migration/invasion,
embolization, survival in the circulation, arrest in a distant
capillary bed, and extravasation into and multiplication within
the distant organ parenchyma. Failure at any of these steps could
block the entire metastatic process and may lead to ‘‘dormant
cancer cells and dormant micrometastases’’. Surgical removal of
the primary tumor might then lead to active growth [38]. Because
tumor spread is responsible for the majority of deaths of cancer
patients, the development of therapeutic agents that inhibit tumor
metastasis is of paramount importance [39,40,41,42,43,44,45,
46,47].
One of us predicted previously [5] that the cytoplasmic end of
CHL1 protein might interact with the cytoskeleton and might
induce/regulate filopodia formation driving tumor cell migration
and invasion [41,45,46]. CHL1 behavior in cancer is thus strikingly
similar to L1 [10,40] and LOX which both work through the actin
network.
This study suggested that CHL1 might contribute to cancer
invasive growth and metastasis. It might act either as a tumor
Figure 3. Expression profiling of CHL1 in primary breast, lung and renal tumors. A. The relative CHL1 mRNA level (R) in breast cancer (BC).
N0 – without metastases, N1–2 – metastases in regional lymph nodes. Samples #1, 2 (Stage I), #3-22 (Stage II), #23 (Stage IV); samples #3-9 (Grade
1), #10-21 (Grade 2). B. The relative CHL1 mRNA level (R) in lung cancer (NSCLC). SCC – lung squamous cell carcinomas, ADC – lung
adenocarcinomas, N – normal samples from cancer free healthy donors; N0 – without metastases, N1–2 – metastases in regional lymph nodes; I, II and
III – Stages. C. The relative CHL1 mRNA level (R) in renal cancer (RCC). CC-RCC – clear cell renal carcinomas, pRCC – papillary renal carcinomas; N0 –
without metastases, N1–2 – metastases in regional lymph nodes; I, II and III – Stages.
doi:10.1371/journal.pone.0015612.g003
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growth, Fig. 1, Table 1). CHL1 therefore could belong to the new
rapidly growing category of cancer genes that may function either
as TSGs or oncogenes [32,41,43,46,47,48]. During initial growth
CHL1 is not expressed (silenced) in tumor cells to facilitate in situ
tumor growth. Re-expression of CHL1 on the edge of the tumor
mass and around tumor vessels could promote migration and local
invasive growth and furthermore allow initiating the metastatic
process. Thus, our results along with the findings that CHL1 was a
mutated candidate cancer-associated gene in colon cancer [1]
suggested that this type of recognition receptors may indeed have
dual roles in carcinogenesis. The mutations discovered in the
extra-cellular part of CHL1 could afford a therapeutic antibody to
selectively treat patients [1]. This validates CHL1 as a novel target
for personalized immune intervention in cancers expressing
mutated CHL1. New therapeutic small inhibitors directed at
CHL1 could be effective in restraining new tumor formation from
dormant micrometastases.
Our results indicated that the CHL1 gene could be important
for the development of major human cancers, and also allowed to
suggest a hypothesis on a probable dual role of CHL1, although
only for three types of cancer (ovary, colon and breast) supportive
data were thus far obtained. A frequent decrease of an expression
level was prevalent for 11 of 19 tumor types and statistically
significant for breast, colon, rectum, thyroid, kidney and small
intestine cancer.
Our data also supported the role of CHL1 as a potentially novel
biomarker in the early pathogenesis of two major histological types
of renal cancer both CC-RCC and pRCC. Results derived with 7
RCC cell lines suggested them as a potential model system for
study of methylation role in CHL1 silencing.
Materials and Methods
Cancer profiling arrays analysis
Cancer Profiling Arrays I and II (154 and 241 samples
respectively, overall 19 different types of cancers namely, breast,
kidney, rectum, colon, stomach, skin, thyroid, small intestine,
bladder, vulva, pancreas, prostate, cervix, testis, lung, ovary,
uterus, liver, trachea) purchased from BD Biosciences Clontech
(Palo Alto, CA), were used to analyze the expression of the CHL1
gene in normal and tumor tissues. Full sample information for
Array I and II is presented in Clontech Catalog: No. 7841-1 and
No. 631777 respectively (see ‘‘Arrays Information S1’’).
We analyzed only informative samples with clear ratio of
normal-tumor spots intensity. The information for samples of the
Cancer Profiling Array I is presented below.
1. Breast. Most of the tumors are infiltrating ductal (DC),
intraductal (IC) and lobular (LC) carcinomas. Stage I: 2Q, 2R, 2S,
2T, 2U, 4S, 4D, 4F. Stage II: 2W, 4E, 4L, 4N. Stage III: 4A, 4B,
4H, 4J, 4M. Coordinates of 18 metastatic (m) tumors are 2B, 2C,
2D, 2E, 2H, 2I, 2J, 2M, 2N, 2P, 4H, 4J, 4L, 4O, 4P, 4R, 4S, 4U.
Coordinates of metastases are 4G, 4I, 4K.
2. Uterus. Most of the tumors are adenocarcinomas (ADC).
Stage I: 8C, 8F, 8H, 8I, 8J, 8K, 8L, 8M, 8N, 8O, 8P, 8Q, 8R, 8S,
8U, 8X, 8Y, 8BB, 8CC, 8DD, 8EE, 8FF, 10A, 10B, 10C. Stage II:
8T. Coordinates of metastatic tumors 8W and 8AA, Stage III.
Coordinates of metastases are 8V, 8Z.
3. Colon. All tumors are ADC. Stage I: 14L. Stage II: 14M,
14P, 14Q, 14AA. Stage III: 14S, 14U, 14V, 14Y, 14BB. Other
samples have no information about the Stage. Coordinates of 9
metastatic tumors are 14E, 14N, 14P, 14U, 14W, 14Y, 14CC,
16A, 16C. Coordinates of metastases are 14O, 14T, 14V, 14X.
4. Stomach. Most of the tumors are ADC. There is no
information about the Stage. Coordinates of 11 metastatic tumors
are 20A, 20B, 20E, 20F, 20H, 20I, 20K, 20S, 20T, 20V, 20X.
5. Ovary. Stage I: 24B, 24D, 24E. Stage II: 24F. Stage III:
24A, 24G, 24H, 24J, 24L. Most tumors are ADC. Coordinates of
metastatic tumors are 24J, 24L, 24M, 24N. Coordinates of
metastases are 24I, 24K.
6. Cervix. 24X (adenosquamous carcinoma).
7. Lung. Stage I: 28E (squamous cell carcinoma, SCC), 28F
(carcinoid), 28H (SCC), 28I (ADC), 28J (ADC), 28K (SCC), 28L
(bronchiolo-alveolar adenocarcinoma, BAC), 28M (SCC), 28N
(ADC). Unknown Stage: 28A (SCC), 28B (BAC), 28C (SCC), 28D
(SCC), 28G (SCC), 28O (m, ADC), 28P (m, BAC), 28Q (SCC),
28R (carcinoid), 28S (ASC), 28T (SCC), 28U (SCC).
Table 4. The CHL1 mRNA changes using microarrays and RT-
qPCR.
Cancer Changes Frequency of CHL1 mRNA changes, %
Microarrays qPCR
BC Increase 11 (7/61) 22 (5/23)
Decrease 75 (46/61) 61 (14/23)
RCC Increase 13 (3/23) 3 (1/30)
Decrease 78 (18/23) 87 (26/30)
doi:10.1371/journal.pone.0015612.t004
Table 2. The frequency (FD) and the level (LDav) of the CHL1
mRNA decrease in lung cancer (ADC and SCC types).
Group ADC SCC
Without metastases FD,% 38 (3/8) 83 (5/6)
aLDav 9 (2—100) 9 (4—21)
bP nsv ,0.03
With metastases FD,% 33 (2/6) 80 (8/10)
LDav 17 (2—35) 10 (2—44)
P nsv ,0.02
Total FD,% 38 (5/14) 81 (13/16)
LDav 12 (2—100) 10 (2—44)
P nsv ,0.02
aThe LDav values are shown in fold-change ratios.
bP reflects the difference between group of tumor samples and group of
adjusted normal samples.
The LD range is given in parentheses. nsv - not statistically valid.
doi:10.1371/journal.pone.0015612.t002
Table 3. The frequency (FD) and the level (LDav) of the CHL1
mRNA decrease in renal cancer (CC-RCC).
CC-RCC Stage Total
I II III
FD,% 90 (9/10) 100 (10/10) 70 (7/10) 87 (26/30)
LDav 24 (8—302) 17 (3—93) 13 (3—96) 18 (3—302)
P ,0.02 ,0.02 ,0.02 ,0.01
doi:10.1371/journal.pone.0015612.t003
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(clear cell renal cell carcinoma, CC-RCC), 32B (RCC), 32C
(RCC), 32E (RCC), 32F (transitional cell carcinoma), 32G (RCC),
32H (m, RCC), 32I (oncocytoma), 32J (RCC), 32K (RCC), 32L
(m, RCC), 32M (RCC), 32N (m, RCC), 32O (RCC), 32P (RCC),
32Q (RCC), 32R (RCC), 32S (RCC), 32T (RCC).
9. Rectum. All tumors are ADC. Stage I: 36G. Stage II: 36J,
36F. Stage III: 36C, 36H, 36I, 36L. Coordinates of 6 metastatic
tumors are 36B, 36E, 36L, 36M, 36Q, 36R. Coordinate of
metastasis is 36K.
10. Small intestine. 36Y (m, ADC), 36Z (ADC).
11. Thyroid gland. All tumors are papillary ADC, Stage II:
40D. Stage III: 40C, 40E.
12. Prostate. All tumors are ADC. Stage I: 40M.
13. Pancreas. Unknown Stage: 40U (ADC).
The information for samples of the Cancer Profiling Array II is
shown below.
1. Breast. Stage I: 6E (DC), 6G (mucinous ADC), 6M (DC).
Stage II: 6I (DC), 6K (m, DC), 6L (DC), 6N (DC). Stage III: 6F
(m, DC), 6H (m, DC), 6J (m, LC).
2. Uterus. Stage I: 6T (ADC), 6Z (SCC), 6BB (ADC). Stage II:
6X (SCC), 6AA (ADC). Unknown Stage: 6V (SCC).
3. Ovary. Stage I: 10E (papillary serous cystadenoma), 10K
(mucinous cystadenocarcinoma). Stage II: 10I (ADC), 10J
(leiomyoma). Stage III: 10G (ADC), 10H (CC-ADC), 10M (serous
surface papillary carcinoma), 10N (papillary serous cystadenoma).
Stage IV: 10L (ADC). Unknown Stage: 10F (leiomyoma).
4. Cervix. Stage I: 10Z (ADC), 10AA (SCC), 10BB (SCC).
Stage II: 10V (SCC). Stage III: 10S (m, SCC).
5. Colon. Stage I: 14E (tubulovillous adenoma, other tumors
are ADC), 14F. Stage II: 14L. Stage III: 14H (m), 14I (m), 14J,
14K (m), 14M, 14N (m). Stage IV: 14G (m).
6. Rectum. All tumors are ADC. Stage II: 14X, 14Y, 14Z.
Stage III: 14T, 14V (m), 14W (m), 14AA (m), 14BB (m). Stage IV:
14S (m), 14U (m).
7. Stomach. Most of the tumors are ADC. Stage II: 18E.
Stage III: 18M (m). Stage IV: 18J (m), 18K (m). T3N1Mx: 18F
(m).
8. Thyroid gland. Stage II: 18X (papillary adenocarcinoma,
PAC), 18Y (PAC), 18AA (PAC), 18BB (follicular ADC). Stage III:
18S (m, ADC), 18W (m, PAC). Stage IV: 18T (m, medullary
carcinoma), 18Z (m, PAC). T3N0M0: 18U (PAC).
9. Lung. Stage I: 22I (SCC), 22J (SCC), 22N (SCC). Stage II:
22L (m).
10. Testis. All tumors are seminomas. Stage I: 22V, 22X.
Stage II: 22T. Stage III: 22BB (m). Stage IV: 22AA (m).
11. Kidney. Stage II: 26E (RCC), 26M (epithelial nephro-
blastoma). Stage III: 26H (RCC), 26I (transitional cell carcinoma,
TCC), 26J (clear cell ADC), 26K (m, TCC). Stage IV: 26G (m,
RCC), 26L (m, RCC). Unknown Stage: 26F (oxyphilic adenoma).
T3aNxM0: 26N.
12. Skin. Most of the tumors are melanomas. Stage I: 26S,
26BB. Stage II: 26Y (SCC), 26Z (SCC). Stage III: 26T, 26U, 26W,
26AA. Stage IV: 26V. Unknown Stage: 26X.
13. Bladder. All the tumors are transitional cell carcinomas:
Stage II: 30E, 30H. Stage III: 30F, 30I. Stage IV: 30G.
14. Trachea. T4N1M0: 30L (m); T4N0M0: 30M. T3N1M0:
30N (m).
15. Small intestine. Most of the tumors are ADC. Stage II:
30T, 30V. Stage III: 30S (m), 30U, 30X (m). Stage IV: 30Y (m).
Unknown Stage: 30W (carcinoid).
16. Vulva. All tumors are SCC. Stage II: 34E, 34F, 34G, 34H.
T2aN1M0: 34I (m).
17. Liver. T3N0M0: 34L. T2N0M0: 34M. T2N0M0: 34N.
18. Pancreas. Stage I: 34S (ADC), 34T (ADC). Stage II: 34V
(SCC). Stage IV: 34W (m, ADC). T3NxM0: 34Y (cancer of caput
of pancreas). Unknown Stage: 34X (carcinoid).
19. Prostate. All tumors are ADC. Stage I: 38E. Unknown
Stage: 38F, 38G, 38H.
Totally, there were 90 metastatic samples (with lymph node
metastases) and 12 metastases at distant sites.
The arrays were hybridized with specific CHL1 probes labeled
with
32P-a-deoxycytidine triphosphate according to manufactur-
er’s protocol (Clontech). The images were obtained using the
Packard Cyclone Storage Phosphor System (PerkinElmer, Shelton,
CT).
Tissues specimens and cell lines for RT-qPCR analysis
We analyzed cDNA samples isolated from 30 NSCLC
specimens including 16 SCC and 14 ADC; 39 renal cancer
Figure 4. The relative expression levels of CHL1 in CC-RCC cell lines. The mRNA level of the target gene was normalized to the reference
genes RPN1 and GUSB.
doi:10.1371/journal.pone.0015612.g004
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carcinomas (pRCC) and 23 breast cancer primary tumors
including 19 ductal BC, one lobular BC and 3 mixed lobular-
ductal BC. Accordingly, we used 29, 39 and 23 samples from
adjacent morphologically normal lung, renal and breast tissues as
controls. Six samples of normal lung tissues from healthy donors
were used as additional controls. Paired tumor and non-
cancerous (normal) matched tissues were received from Blokhin
Cancer Research Center, Russian Academy of Medical Sciences.
All tumors were classified according to the International TNM
Classification system [49,50]. These samples were obtained from
patients after surgical resection of primary lung, renal and breast
cancer prior radiation or chemotherapy and stored in liquid
nitrogen. The diagnosis was verified by histopathology and only
samples containing 70–80% or more tumor cells were used in the
study. The samples were collected in accordance to the
guidelines issued by the Ethics Committee of Blokhin Cancer
Research Center, Russian Academy of Medical Sciences
(Moscow). All patients gave written informed consent that is
available upon request. The Ethics Committee of Blokhin
Cancer Research Center, Russian Academy of Medical Sciences
specifically approved this study. The study was done in
accordance with the principles outlined in the Declaration of
Helsinki.
Clear cell renal cancer cell lines TK10, TK164, KRC/Y,
KH39, HN4, Caki1and Caki2 from MTC collection were also
analyzed in the study. Mix of six samples of normal lung tissues
from healthy donors were used as controls.
RNA and cDNA preparation for RT-qPCR
Total RNA was isolated from tumor and matched normal
tissues, renal cancer cell lines using RNeasy Mini Kit (Qiagen,
Netherlands) according to the manufacturer’s instructions. Purified
RNA was quantified using NanoDropH ND-1000 spectrophotom-
eter (NanoDrop Technologies Inc., USA), and the quality was
determined by Bioanalyzer 2100 (Agilent Technologies, USA). All
RNA samples were treated with DNase I and cDNA was
synthesized using MMLV reverse transcriptase and random
hexamers according to standard manufacturer’s protocol (Fer-
mentas, Lithuania).
Analysis of CHL1 expression by RT-qPCR
RT-qPCR was performed essentially as described previously
[51] in total volume of 25 ml in triplicate. The sequences of
primers (F and R) and TaqMan probes (Z) are shown in Table 5.
Final concentrations of primers and probes for target and
reference genes were as follow: CHL1 primers – 300 nM, probe
– 400 nM; GAPDH primers – 300 nM, probe – 150 nM, RPN1
primers – 300 nM, probe – 150 nM, GUSB primers – 300 nM,
probe – 250 nM, B2M primers and probe – 300 nM.
The thermocycler conditions were 10 min at 95uC, then 45
two-step cycles 15 s at 95uC and 60 s at 60uC (ABI 7000 PRISM
Sequence Detection System, Applied Biosystems). The sequences
of the amplicons were verified by sequencing in a 3730 DNA
Analyzer (Applied Biosystems).
RT-qPCR data were analyzed using the relative quantification
method, or DDCq-method [52,53] based on target and reference gene,
in tumor (T) and normal (N) samples comparison. Relative mRNA
level (R) is calculated by formula: R~ntar:gene
 
nref:gene,w h e r en is
mRNA copy number in tumor sample relative normal sample.
n~ 1zE ðÞ
{Cq
  
T
.
1zE ðÞ
{Cq
  
N
~ 2{CEff
q
  
T
.
2{CEff
q
  
N
~
2{DCEff
q .H e r ei sE – reaction efficiency, Cq – quantification cycle,
CEff
q ~Cq log2 1zE ðÞ , effective quantification cycle.
Finally, R~ 2{DCEff
q
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q
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~2{DDCEff
q .
The reaction efficiencies (E) were calculated as described [33] and
their values were 8569% (lung), 93611% (breast), 87610% (renal) for
CHL1;8 9 68% (lung) for GAPDH;8 6 611% (breast) for B2M;8 7 69%
(renal) for RPN1;8 1 69% (renal) for GUSB in tumor and normal
samples. The level of mRNA expression change was calculated as 1/R
and reflected the n-fold factor by which the mRNA content decreased
or increased in the tumor compared to normal tissue.
All preliminary validation steps were performed according to
Gene quantification resource (www.gene-quantification.de). As
reference genes, we used GAPDH and RPN1 for NSCLC, B2M for
BC, and GUSB and RPN1 for RCC. The relative inner variability
between GAPDH, B2M, GUSB and RPN1 mRNA levels was not
higher than 2-fold in tumor (T) and normal (N) tissues, therefore 2-
fold and more mRNA changes for CHL1 were considered as
significant for all types of studied tumors.
Table 5. Primers and probes sequences for CHL1 and reference genes for RT-qPCR.
Symbol/RefSeq ID Gene name
Primers (F, R) and probe (Z) sequences
59R39
CHL1 (CALL)
NM 006614.2
Close homolog of L1
(cell adhesion L1 like)
F: GAACTATCCTTGCCAATGCCAATAT
R: TTCTGCCAGGACACGACTGC
Z: AAGAAAGCACTGTACCCAACCACTGTAGCG
RPN1
NM_002950.3
Ribophorin I F: CACCCTCAACAGTGGCAAGAAG
R: TGCATTTCGCTCACTCTGTCG
Z: CCCTCTGTCTTCAGCCTGGACTGC
GUSB
NM_000181,2
Glucuronidase, beta
b-D-glucuronidase
F: GATGGAAGAAGTGGTGCGTAGG
R: TTAGAGTTGCTCACAAAGGTCACAG
Z: CGTCCCACCTAGAATCTGCTGGCTACTACTT
B2M
NM_004048.2
Beta-2-microglobulin F: ATGAGTATGCCTGCCGTGTG
R: AATTCATCCAATCCAAATGCG
Z: ATCTTCAAACCTCCATGATGCTGCTTACAT
GAPDH
NM _002046.3
Glyceraldehyde-3-phosphate
dehydrogenase
F: GGAGTCAACGGATTTGGTC
R: TGGGTGGAATCATATTGGAACAT
Z: CCTTCATTGACCTCAACTACATGGTTTACAT
doi:10.1371/journal.pone.0015612.t005
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Transcription of Genes) compatible with Relative Quantification
(RQ) software (Applied Biosystems). The program is designed for
mathematical processing of RT-qPCR data in paired normal-
tumor samples. The general features of AEGIS consist of
estimating reaction efficiencies with three different methods
(including calculating efficiency from kinetic curves) and taking it
into account for further data analysis, using the relative
comparative DDCqmethod [52] with several reference genes and
estimating their variability. Also this program allows checking
adjusted normal samples variability and using as paired normal
sample for each tumor sample as one or several normal samples
for all tumor samples.
Statistical analysis
For validation of CHL1 expression differences between normal
and tumor samples and also between tumor samples with and
without metastases we applied Fisher exact test and x
2 criterion.
Nonparametric Wilcoxon test was used for analyzing RT-qPCR
data to compare mRNA content differences of the CHL1 gene and
reference genes for the same samples. We used nonparametric
Kruskal-Wallis and Mann-Whitney tests for the rank order
differences between average relative levels of mRNA in different
groups of samples. P-values,0.05 were considered statistically
significant. All statistical procedures were performed using BioStat
software [54].
Supporting Information
Arrays Information S1 This archive contains detailed infor-
mation about localization and clinical characteristics of all the
tumors (histological type, tumor size, stage, presence of metastases
etc.).
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